Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 May 2022Website:
http://pepgen.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:02:55 GMTDividend
Analysts recommendations
Institutional Ownership
PEPG Latest News
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or "the Company") (NASDAQ:PEPG) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
What type of business is PepGen?
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
What sector is PepGen in?
PepGen is in the Healthcare sector
What industry is PepGen in?
PepGen is in the Biotechnology industry
What country is PepGen from?
PepGen is headquartered in United States
When did PepGen go public?
PepGen initial public offering (IPO) was on 06 May 2022
What is PepGen website?
https://pepgen.com
Is PepGen in the S&P 500?
No, PepGen is not included in the S&P 500 index
Is PepGen in the NASDAQ 100?
No, PepGen is not included in the NASDAQ 100 index
Is PepGen in the Dow Jones?
No, PepGen is not included in the Dow Jones index
When was PepGen the previous earnings report?
No data
When does PepGen earnings report?
The next expected earnings date for PepGen is 08 November 2024